News

Murugesan Manoharan, MD, FRACS, offers observations about prostate cancer care at Miami Cancer Institute.

Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.

Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP

Tirabrutinib has received orphan drug status from the FDA and is being studied in the phase 2 PROSPECT study for patients with primary central nervous system lymphoma.

The first orphan drug designation from the FDA has been received by FORE Biotherapeutics and for the FORE8394 program for patients with primary brain and central nervous system malignancies.

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

The FDA has okayed PD-1 inhibitor for the treatment of adults with advanced Merkel cell carcinoma.

In the largest study of CAR T-cell therapy, ZUMA-7, a key secondary end point was met with axicabtagene ciloleucel treatment in patients with relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.

ISB 1442, a 2+1 biparatopic bispecific antibody that has CD38 and CD47 targeting domains, has received an orphan drug designation from the FDA and is being assessed in a phase 1/2 clinical trial for patients with multiple myeloma.

A study of isatuximab and cemiplimab in 3 lymphoma subtypes will not continue, for reasons unrelated to safety.

Ripretinib will be evaluated in a phase 3 trial for patients with gastrointestinal stromal tumor after being added to the NCCN guidelines and receiving 2 breakthrough therapy designations from the FDA.

At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.

PBP1510 has received a fast track designation from the FDA for patients with unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least 1 prior line therapy.

In an interview, Randall Oyer, MD, explained the need to improve the impact of treatment-related adverse reactions using a multidisciplinary approach to enhance the lives of cancer survivors.

Anti-VISTA therapy may be the therapy type to be used with PD-1/PD-L1 inhibitors to treat patients with advanced solid tumors, expert say. One agent, KVA12123, has just entered phase 1 clinical research.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.

In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.

The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer

The combination of CDK9 plus BTK inhibition has already demonstrated synergistic clinical efficacy vs BTK inhibition alone. Now, a clinical trial collaboration will evaluate PRT2527 and zanubrutinib for patients with hematologic malignancies.

A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.

The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Yuri E. Nikiforov, MD, PhD, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which has significantly influenced the thyroid cancer space.

In an interview with Targeted Oncology, Yuri E. Nikiforov, MD, PhD, discussed what led to the reclassification of NIFTP and the incidence of thyroid cancer in patients.

Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.

The newly approved supplemental new drug application for Illuccix by the FDA will enable patients with prostate cancer to be identified and selected for radioligand therapy.